| Literature DB >> 7491810 |
Abstract
The potential outcomes of a Phase II schistosomiasis vaccine trial are explored using mathematical models which assume some natural immunity and a vaccine providing partial protection for a limited time. Analyses suggest that vaccination may have only a limited impact on life-long cumulative worm burdens and may lead to increased susceptibility and higher worm burdens at some ages, a "rebound" effect which results reduced opportunity to acquire natural immunity. There is a trade-off between the degree and duration of vaccine-induced protection; long-lived vaccines may be preferable to vaccines giving greater protection but for a shorter time.Entities:
Mesh:
Substances:
Year: 1995 PMID: 7491810 DOI: 10.1016/0264-410x(95)00083-d
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641